Specialty	Obstetrics and Gynecology
Subspecialty	Gynecologic Oncology
Clinical Interests	GYN Cancer
	Ovarian Cancer
	Ultrasound
	Cervical Cancer
	Diagnostic Imaging/Testing
	LEEP procedures
	Minimally Invasive Techniques
	Uterine Cancer
	Vaginal Cancer
	Vulvar Cancer
Languages	English
Gender	Male
E-mail	david.fishman@mssm.edu
Education and Training	MD, University of Texas
	Residency, Ob-Gyn, Yale University School of Medicine
	Fellowship, Gynecology Oncology, Yale University School of Medicine
Awards	2009 Best Doctors New York Magazine
	2007 NIH NCI EDRN Award
	2006 Honorary Chairman Presidents Physician Advisory Board
	2005 Keynote Lecturer Society of Gynecologic Oncologists of Canada
	2005 American College of Obstetricians and Gynecologists Lecturer
	2005 Shufelt Society Lecturer
	2005 American Gynecological and Obstetrical Society Lecturer
	2005 Susan Teck Lecturer George Washington University
	2005 Keynote Lecturer University of Wisconsin
	2005 Invited Lecturer Oncology World Congress
	2005 Member AOA

David A. Fishman, MD joins the faculty of the Mount Sinai School of Medicine from New York University Medical School, where he was Professor of Obstetrics and Gynecology, and Director of Gynecologic Oncology.

An internationally recognized gynecologic oncologist, Dr. Fishman is especially noted for his innovative research on the regulation of ovarian metastasis and in developing new methods for the detection of early stage ovarian carcinoma. He established The National Ovarian Cancer Early Detection Program in 1999 with a grant from the National Cancer Institute and philanthropic support. He is currently the Director of this program.

Dr. Fishman received his medical degree from Texas Tech School of Medicine and completed his residency and fellowship in Obstetrics and Gynecology and Gynecologic Oncology at the Yale University School of Medicine.

Dr. Fishman has authored over 230 scientific papers, abstracts, and book chapters and several books on gynecologic malignancies. His research has received awards from the National Institutes of Health, National Cancer Institute, Society of Gynecologic Oncologists, Gynecologic Cancer Foundation, American Cancer Society, the Society for Gynecologic Investigation, Berlex Foundation and multiple philanthropic agencies. He serves as an editor for three journals and ad hoc reviewer for 43 medical and scientific journals and is a member of national and international cancer institute study sections from the National Cancer Institute and Centers for Disease Control to the Royal College of Obstetricians and Gynecologists.

His membership in many medical and honor societies and patient advocacy groups include the American Gynecologic and Obstetrical Society, Society for Gynecologic Investigation, AOA, the Society of Gynecologic Oncologists and the National Ovarian Cancer Coalition. He frequently lectures worldwide on women's cancers and early detection techniques.

Education and Training	MD, University of Texas
	Residency, Ob-Gyn, Yale University School of Medicine
	Fellowship, Gynecology Oncology, Yale University School of Medicine
Board Certification	Gynecologic Oncology
	Obstetrics and Gynecology

Specialty	Obstetrics and Gynecology
Subspecialty	Gynecologic Oncology
Clinical Interests	GYN Cancer
	Ovarian Cancer
	Ultrasound
	Cervical Cancer
	Diagnostic Imaging/Testing
	LEEP procedures
	Minimally Invasive Techniques
	Uterine Cancer
	Vaginal Cancer
	Vulvar Cancer
Languages	English
Board Certification	Gynecologic Oncology
	Obstetrics and Gynecology

As an academic gynecologic oncologist, Dr. Fishman is committed to the development of a comprehensive multidisciplinary program that would decrease the morbidity and mortality of gynecologic malignancies and improve women's healthcare.

His academic career has focused on the ovarian tumor microenvironment and applying our understanding of the processes of carcinogenesis, invasion, and metastasis to develop relevant biomarkers using proteomic technologies and novel sonographic techniques for early detection, cancer specific therapeutics, and means for chemoprevention.

In 1999 the National Ovarian Cancer Early Detection Program (NOCEDP), for which he serves as Director and Principal Investigator, was initiated by NCI support and has achieved international recognition for the clinical application of innovative basic science regarding ovarian cancer. To date this program has evolved into an international collaborative effort from Sri Lanka to the US of over 200 physicians and scientists dedicated to the development of effective means for the accurate detection of early stage disease, chemoprevention, and cancer specific therapeutics. The NOCEDP represents an integrated program of clinicians, scientists, and institutions with complementary expertise unifying to facilitate early detection, treatment and prevention of ovarian cancer.

Wang FQ, Barfield E, Fishman D. Silencing of VEGFR-2 by RNA Interference Inhibits LPA-induced Invasion. Eur J Cancer 2009;.

Hope JM, Wang FQ, Whyte JS, Ariztia EV, Abdalla W, Long K, Fishman DA. LPA receptor 2 mediates LPA-induced endometrial cancer invasion . Gynecol Oncol 2009; 112: 215-223.

Gogoi R, Kudla M, Gil O, Fishman D. The Activity of Medroxyprogesterone Acetate, an Androgenic Ligand, in Ovarian Cancer Cell Invasion. Reprod Sci 2008 Oct; 15(8): 846-852.

Devine KM, Smicun Y, Hope JM, Fishman DA. S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment are mediated by Gi and Rac. Gynecol Oncol 2008 Aug; 110(2): 237-245.

Fleischer AC, Lyshchik A, Jones HW Jr., Crispens M, Loveless M, Andreotti RF, Williams PK, Fishman DA. Contrast-enhanced transvaginal sonography of benign versus malignant ovarian masses: preliminary findings. J Ultrasound Med 2008 Jul; 27(7): 1011-1018.

Cowden Dahl K, Symowicz J, Ning Y, Gutierrez E, Fishman DA, Adley B, Stack MS, Hudson L. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res 2008 Jun 15; 68(12): 4606-4613.

Feng W, Marquez RT, Lu Z, Liu J, Lu KH, Issa JP, Fishman DA, Yu Y, Bast RC Jr. Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer 2008 Apr; 112(7): 1489-1502.

Gil OD, Lee C, Ariztia EV, Wang FQ, Smith PJ, Hope JM, Fishman DA. Lysophosphatidic acid (LPA) promotes E-cadherin ectodomain shedding and OVCA429 cell invation in an uPA-dependent manner. Gynecol Oncol 2008 Feb; 108(2): 361-369.

Liu C, Shea N, Rucker S, Harvey L, Russo P, Saul R, Lopez MF, Mikulskis A, Kuzdzal S, Golenko E, Fishman D, Vonderheid E, Booher S, Cowen E, Hwang S, Whiteley G. Proteomic Patterns for Classification of Ovarian Cancer and CTCL Serum Samples Utilizing Peak Pairs Indicative of Post-Translational Modifications. Proteomics 2007 Nov; 7(22): 4045-4052.

Smicun Y, Gil O, Devine K, Fishman DA. S1P and LPA have an attachment-dependent regulatory effect on invasion of ovarian cancer cells. Gynecol Oncol 2007 Nov; 107(2): 298-309.